bluuebunny/crossref_metadata_2025_split huggingface dataset:
Reactions of 5‐Dialkylamino‐1,2,3‐thiadiazole‐4‐carbaldehydes with Amines as a Method for the Synthesis of 1,2,3‐Triazole‐4‐carbothioamides.
Authors: Glukhareva T. V. , Morzherin Yu. Yu. , Dyudya L. V. , Malysheva K. V. , Tkachev A. V. , Padva A. , Bakulev V. A. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Domino Ring‐Closing Metathesis/Intramolecular Transfer of an Alkenyl Subunit: A Direct Formation of Functionalized Butenolides and Pyrones from α,β‐ and β,γ‐Unsaturated Esters.
Authors: Virolleaud Marie‐Alice , Piva Olivier 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
6‐(3,4‐Difluorobenzoyl)‐3‐ [2‐(4‐pyridyl)ethyl]‐1,3‐benzothiazol‐2(3H)‐one
Authors: Oezbey Sueheyla , Goekhan Nesrin 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Mono‐ and Diadducts and Bicyclic Adducts in Reactions of 2,3‐Dicyano‐1‐ethylpyrazinium Cation with C‐ and O‐Nucleophiles.
Authors: Slepukhin P. A. , Rusinov G. L. , Charushin V. N. , Filyakova V. I. , Karpenko N. S. , Krivolapov D. B. , Litvinov I. A. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Kinetic Resolution of Heterocyclic Amines by Reaction with Optically Active Acid Chlorides. The Effect of Reaction Conditions on the Diastereoselectivity of Acylation of (.+‐.)‐3‐Methyl‐2,3‐dihydro‐4H‐1,4‐benzoxazine.
Authors: Krasnov V. P. , Levit G. L. , Korolyova M. A. , Bukrina I. M. , Sadretdinova L. Sh. , Andreeva I. N. , Charushin V. N. , Chupakhin O. N. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
2‐[6‐(3‐Chlorophenyl)‐2,4‐dioxoperhydropyrimidin‐3‐yl]ethyl Morpholine‐4‐carbodithioate
Authors: Koeysal Yavuz , Isik Samil , Septioglu Ebubekir , Calis Uensal 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
5,6,7,8‐Tetrafluoro‐4‐hydroxycoumarin Derivatives in Reactions with o‐Phenylenediamine.
Authors: Burgart Ya. V. , Shcherbakov K. V. , Saloutin V. I. , Chupakhin O. N. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Reaction of 2‐Acetyl‐5‐methyl‐2H‐1,2,3‐diazaphosphole with Butane‐2,3‐diol.
Authors: Khusainova Narkis G. , Mostovaya Olga A. , Azancheev Nail M. , Litvinov Igor A. , Krivolapov Dmitry B. , Cherkasov Rafael A. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
The Inhibition of the Fungus Botrytis cinerea by an Eremophilane Phytoalexin Analogue.
Authors: Collado Isidro G. , Deligeorgopoulou Anthina , Hanson James R. , Hitchcock Peter B. , Macias‐Sanchez Antonio J. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
An Efficient Large Scale Synthesis of Nateglinide.
Authors: Chandrasekhar Batchu , Sawanth Mangesh S. , Naik Sameer J. , Gaikwad Nandakumar B. , Kulkarni Pramila V. , Bhirud Shekar B. 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
In vitro and in vivo Antibacterial Activities of the Tricyclic Ketolide TE‐802 and Its Analogues.
Authors: Ono Takeo , Kashimura Masato , Suzuki Keiko , Oyauchi Rika , Miyachi Junko , Ikuta Hiroshi , Kawauchi Hiroyuki , Akashi Toshi , Asaka Toshifumi , Morimoto Shigeo 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Inhibition of PTP1B by Metabolites from Micromucor ramannianus var. angulisporus CRM000232.
Authors: Oh Hyuncheol , Kim Beom Seok , Bae Eun Young , Kim Min Soo , Kim Bo Yeon , Lee Hyang Burm , Kim Chang‐Jin , Ahn Jong Seog 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Three New Compounds from the Plant Lippia alva as Inhibitors of Chemokine Receptor 5 (CCR5).
Authors: Hegde Vinod R. , Pu Haiyan , Patel Mahesh , Das Pradip R. , Strizki Julie , Gullo Vincent P. , Chou Chuan‐Chu , Buevich Alexei V. , Chan Tze‐Ming 
Published: February 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance
Authors: Claus Elizabeth B. , Horlacher Andres , Hsu Liangge , Schwartz Richard B. , Dello‐Iacono Donna , Talos Florian , Jolesz Ferenc A. , Black Peter M. 
Published: February 2005

AbstractBACKGROUNDNo age‐adjusted or histologic‐adjusted assessments of the association between extent of resection and risk of either recurrence or death exist for neurosurgical patients who undergo resection of low‐grade glioma using intraoperative magnetic resonance image (MRI) guidance.METHODSThe current data included 156 patients who underwent surgical resection of a unifocal, supratentorial, low‐grade glioma in the MRI suite at Brigham and Women's Hospital between January 1, 1997, and January 31, 2003. Estimates of disease‐free and overall survival probabilities were calculated using Kaplan–Meier methodology. The association between extent of resection and these probabilities was measured using a Cox proportional hazards model. Observed death rates were compared with the expected death rate using age‐specific and histologic‐specific survival rates obtained from the Surveillance, Epidemiology, and End Results Registry.RESULTSPatients who underwent subtotal resection were at 1.4 times the risk of disease recurrence (95% confidence interval [95% CI], 0.7–3.1) and at 4.9 times the risk of death (95% CI, 0.61–40.0) relative to patients who underwent gross total resection. The 1‐year, 2‐year, and 5‐year age‐adjusted and histologic‐adjusted death rates for patients who underwent surgical resection using intraoperative MRI guidance were 1.9% (95% CI, 0.3–4.2%), 3.6% (95% CI, 0.4–6.7%), and 17.6% (95% CI, 5.9–29.3%), respectively: significantly lower than the rates reported using national data bases.CONCLUSIONSThe data from the current study suggested a possible association between surgical resection and survival for neurosurgical patients who underwent surgery for low‐grade glioma under intraoperative MRI guidance. Further study within the context of a large, prospective, population‐based project will be needed to confirm these findings. Cancer 2005. © 2005 American Cancer Society.
Bortezomib in recurrent and/or refractory multiple myeloma
Authors: Jagannath Sundar , Barlogie Bart , Berenson James R. , Singhal Seema , Alexanian Raymond , Srkalovic Gordan , Orlowski Robert Z. , Richardson Paul G. , Anderson Jessica , Nix Darrell , Esseltine Dixie L. , Anderson Kenneth C. 
Published: February 2005

AbstractBACKGROUNDBortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its activity in patients with renal impairment has not been studied to date.METHODSResponse rates, safety, and 20S proteasome activity were assessed in relation to baseline creatinine clearance (CrCl) among patients with recurrent and/or refractory myeloma (n = 256 patients) who were treated with bortezomib in 2 Phase II trials. Bortezomib was administered by intravenous bolus on Days 1, 4, 8, and 11 of a 21‐day cycle at 2 doses, 1.0 mg/m2 (n = 28 patients) and 1.3 mg/m2 (n = 228 patients).RESULTSOf 10 patients with CrCl ≤ 30 mL/minute, 7 patients completed the protocol‐specified 8 cycles of treatment; 4 patients received the 1.3 mg/m2 bortezomib dose, and 3 patients received the 1.0 mg/m2 bortezomib dose. Using the European Group for Blood and Marrow Transplantation criteria, responses were assigned by an independent committee to 3 of the 10 patients (2 partial responses and 1 minimal response), a response rate similar to that of the overall treated population. Patients with CrCl > 80 mL/minute (n = 105 patients), 51–80 mL/minute (n = 99 patients), and ≤ 50 mL/minute (n = 52 patients) had similar rates of discontinuation and similar adverse event profiles. Renal function did not appear to affect the 1‐hour postdose proteasome inhibition or its recovery.CONCLUSIONSClinical experience in a limited number of patients with impaired renal function suggests that bortezomib provides clinical benefit with manageable toxicities in this high‐risk population. Cancer 2005. © 2005 American Cancer Society.
Cerebrospinal fluid‐disseminated meningioma
Authors: Chamberlain Marc C. , Glantz Michael J. 
Published: February 2005

AbstractBACKGROUNDIntracranial meningiomas are common and comprise 20% of all primary brain tumors. Meningiomas infrequently metastasize; however, to the authors' knowledge there are limited data regarding the spread of disease through cerebrospinal fluid (CSF).METHODSEight of 200 consecutive patients (4%) with meningiomas manifested CSF dissemination. CSF cytology was positive in all patients, and neuroradiographic studies were consistent with CSF dissemination in eight patients. The patients (6 women and 2 men) ranged in age from 24–87 years (mean age, 52 years). All patients had undergone prior surgery (range, one to five surgeries; median, two surgeries), radiotherapy (involved‐field radiotherapy in seven patients and stereotactic radiotherapy in six patients), and chemotherapy (hydroxyurea in eight patients). Multiple sites of metastases were seen in all patients and were both within the nervous system (subarachnoid or ventricular tumor: intracranial in eight patients, spinal cord in four patients) and extraneural (subcutaneous, cervical lymph nodes, orbit, or pulmonary in five patients). Treatment utilized both systemic chemotherapy (temozolomide in four patients, irinotecan in three patients, hydroxyurea in three patients, interferon‐α in two patients, and doxorubicin plus ifosfamide in one patient) and intraventricular chemotherapy (liposomal cytosine arabinoside in seven patients, thiotepa in one patient, and busulfan in one patient).RESULTSTreatment‐related toxicity was seen in eight patients, including chemical meningitis in eight patients (Grade 2), neutropenia in five patients (Grade 2 in four patients and Grade 3 in one patient), fatigue in one patient (Grade 2), and gastrointestinal toxicity in one patient (Grade 2). The best response was stable disease in seven patients and progressive disease in one patient. The response duration ranged from 2–31 months (median, 3.5 months). The median survival was 5.5 months, and 3 patients were alive with disease at the time of last follow‐up.CONCLUSIONSThe treatment of CSF‐disseminated meningioma, although feasible and comparatively nontoxic, was associated with modest outcomes despite combined systemic and intraventricular chemotherapy. Cancer 2005. © 2005 American Cancer Society.
On hydrodynamics of viscoelastic fluids
Authors: Lin Fang‐Hua , Liu Chun , Zhang Ping 
Published: February 2005

AbstractIn this paper, we study a hydrodynamic system describing fluids with viscoelastic properties. After a brief examination of the relations between several models, we shall concentrate on a few analytical issues concerning them. In particular, we establish local existence and global existence (with small initial data) of classical solutions for an Oldroyd system without an artificially postulated damping mechanism. © 2005 Wiley Periodicals, Inc.
Phytoplankton monitoring by high performance flow cytometry: A successful approach?
Authors: Rutten Thomas P. A. , Sandee Ben , Hofman Angelo R. T. 
Published: February 2005

AbstractBackgroundRegular phytoplankton monitoring in Dutch coastal waters is performed as an indicator of the ecological state of these waters. The monitoring program is focused on temporal and spatial changes of species composition and abundance. Flow cytometry has been introduced to provide additional information, to improve ecosystem understanding, and to increase the efficiency of analysis and reportage.MethodsPhytoplankton community abundance and composition were routinely determined by flow cytometry and microscopy at six locations in the North Sea over three annual cycles between 2000 and 2003. Supplementary measurements were also made for fluorescence (chlorophyll‐a and other pigments) and, in combination with flow cytometric and microscopic data, were used to determine phytoplankton abundance and composition as a function of their size distribution. Real‐time imaging of species was also used to identify species on the basis of their flow cytometric optical characteristics.ResultsFlow cytometric analysis took 15 min on average. Analysis including data processing, and Web site reportage took less than 1 h. Phytoplankton concentrations (cells/ml), biomass (fluorescence/ml), and concentration of phycoerythrin‐ or phycocyanin‐containing cells (cells/ml) as a function of their algal size were produced every 2 weeks on average. The phytoplankton integrated annual concentration and biomass were used as ecological indicators for overall phytoplankton status. Real‐time imaging of cells in flow enabled the identification of dominant species and was applied as an early warning system for Phaeocystis spp.ConclusionsThe reproducibility and count precision due to the large number of observations of the flow cytometric technique provided reliable data for monitoring long‐term trends. Flow cytometrically based analyses extended the lower detection limit (<0.5 μm) of analysis beyond the capabilities of other techniques such as the relation between small and larger phytoplankton, the relation between cell counts and biomass as a function of cell size, but also the ability to monitor and report on blooms of harmful algae. A good correlation was found between concentrations (cells/ml) measured by flow cytometry and microscopy. In practice, flow cytometric analysis of a single marine sample took 15 min on average. © 2005 Wiley‐Liss, Inc.
Lymphocyte‐expressed BILL‐cadherin/cadherin‐17 contributes to the development of B cells at two stages
Authors: Ohnishi Kazuo , Melchers Fritz , Shimizu Takeyuki 
Published: February 2005

AbstractThe gene encoding BILL‐cadherin/cadherin‐17, a nonclassical cadherin expressed on B lymphocytes in a stage‐and‐site‐specific manner, was inactivated by targeted disruption of its transmembrane/cytoplasmic portion‐encoding parts. BILL‐cadherin deficiency caused a threefold proB cell accumulation, as well as a reduction to half of the numbers of immature B cells in bone marrow. In spleen, CD21hiCD23lo marginal zone B cells were found reduced and the structure of the marginal zone was impaired. In addition, the size and number of germinal center as well as the number of PNA+ cells were significantly reduced in BILL‐cadherin‐deficient mice. In the peritoneal cavity of mutant mice IgM+Mac‐1+CD5+ B1a cell, that express high BILL‐cadherin in wild‐type mice, was also reduced in number. The IgG1 and IgG3 antibody response to the T‐independent antigen, TNP‐Ficoll, was impaired in the mutant mice. These results indicate that BILL‐cadherin participates in B lymphocyte development at least at two stages, first at the transition of pro/preB‐I cells to preB‐II cells possibly in association with surrogate light chain in bone marrow, and later at the point of development, accumulation and reactiveness of immature B cells in spleen.
Epstein‐Barr virus latent membrane protein 1 induces the matrix metalloproteinase‐1 promoter via an Ets binding site formed by a single nucleotide polymorphism: Enhanced susceptibility to nasopharyngeal carcinoma
Authors: Kondo Satoru , Wakisaka Naohiro , Schell Michael J. , Horikawa Toshiyuki , Sheen Tzung‐Shiahn , Sato Hiroshi , Furukawa Mitsuru , Pagano Joseph S. , Yoshizaki Tomokazu 
Published: February 2005

AbstractThe Epstein‐Barr Virus (EBV) latent membrane protein 1 (LMP1) has a significant role in several malignancies, including nasopharyngeal carcinoma (NPC). LMP1 is the principal oncoprotein, and we have shown that it also induces a set of factors that mediates invasion, angiogenesis and metastasis. Matrix metalloproteinase‐1 (MMP1) is also involved in several malignancies. A single guanine insertion polymorphism (2G) in the MMP1 promoter creates an Ets binding site that causes high levels of transcription and correlates with risk for some malignancies. Here, we evaluate the impact of this2Ginsertion type on NPC. We genotyped 44 Japanese and 39 Taiwanese NPC patients, as well as 58 Japanese and 23 Taiwanese healthy controls. The proportion of2Ghomozygotes was higher in the NPC groups than in controls (Japanese:p= 0.02, odds ratio (OR) = 2.49; Taiwanese:p= 0.02, OR = 3.66). An analysis of overall survival rates in the patients with NPC, and the1G/1Ggenotype disclosed a favorable prognosis (5‐year survival rate = 100%,p= 0.04). Multivariate analysis showed that1G/1Ghas independent prognostic significance. We also examined whether LMP1 enhances MMP1 expression in epithelial cells in culture. LMP1‐transfected cells with2G/2Ggenotype expressed MMP1, which was abolished by activator protein‐1 (AP1) dominant‐negative (DN) and Ets‐DN. LMP1 also induced active MMP3, which can cleave latent MMP1, and AP1‐DN and Ets‐DN suppressed the MMP3 expression. These results suggest that LMP1‐induced MMP1 and MMP3 are closely linked and show that LMP1 activates MMP1 via an Ets binding site formed by2G, which is a candidate marker for both risk and prognosis of NPC. © 2005 Wiley‐Liss, Inc.
Breast cancer risk associated with genotypic polymorphism of the mitosis‐regulating gene Aurora‐A/STK15/BTAK
Authors: Lo Yen‐Li , Yu Jyh‐Cherng , Chen Shou‐Tung , Yang Hsin‐Chou , Fann Cathy S.J. , Mau Yi‐Chien , Shen Chen‐Yang 
Published: February 2005

AbstractAneuploidy, an abnormal number of chromosomes, is relatively common and occurs early in breast cancer development. This observation supports a breast tumorigenic contribution of mechanisms responsible for maintaining chromosome number stability in which centrosomes play an essential role. We therefore speculated that the Aurora‐A/STK15/BTAK gene, implicated in the regulation of centrosome duplication, may be associated with breast tumorigenesis. To test this hypothesis, we conducted a case‐control study of 709 primary breast cancer patients and 1,972 healthy controls, examining single‐nucleotide polymorphisms (SNPs), including a suggested functional Phe31Ile SNP, in Aurora‐A. We were also interested in knowing whether any association between Aurora‐A and breast cancer was modified by reproductive risk factors reflecting susceptibility to estrogen exposure. Our hypothesis is that, since estrogen is known to promote breast cancer development via its mitogenic effect leading to malignant proliferation on breast epithelium and since Aurora‐A is involved in regulating mitosis, the discovery of a joint effect between the Aurora‐A genotype and reproductive risk factors on cancer risk might yield valuable clues to the association of breast tumorigenesis with estrogen. Support for this hypothesis came from the following observations. (i) Two SNPs in Aurora‐A were significantly associated with breast cancer risk (p < 0.05). (ii) Haplotype analyses, based on different combinations of multiple SNPs in Aurora‐A, revealed a strong association with breast cancer risk; interestingly, the genotypic distribution of the suggested functional Phe31Ile SNP was not significantly different between breast cancer patients and controls, but the specific haplotype containing the putative at‐risk Ile allele was more common in patients. (iii) This association between risk and putative high‐risk genotypes was stronger and more significant in women thought to be more susceptible to estrogen, i.e., those with a longer interval between menarche and first full‐term pregnancy. (iv) The protective effect conferred by a history of full‐term pregnancy was significant only in women with a putative low‐risk genotype of Aurora‐A. Our study provides new findings supporting the mutator role of Aurora‐A in breast cancer development, suggesting that breast cancer could be driven by genomic instability associated with variant Aurora‐A, the tumorigenic contribution of which could be enhanced as a result of increased mitosis due to estrogen exposure. © 2005 Wiley‐Liss, Inc.
HPV in situ hybridization: Impact of different protocols on the detection of integrated HPV
Authors: Hopman Anton H.N. , Kamps Miriam A. , Smedts Frank , Speel Ernst‐Jan M. , Herrington C. Simon , Ramaekers Frans C.S. 
Published: February 2005

AbstractAlthough there is consensus that HPV integration is common in invasive cervical carcinomas and uncommon or absent in low‐grade uterine cervical intraepithelial neoplasia (CIN I), estimates for HPV integration in CIN II/III range from 5 to 100% using different PCR‐based and in situ hybridization (ISH) approaches. It has been suggested that HPV integration can be identified using ISH by scoring of punctate signals. The increased sensitivity of fluorescence ISH (FISH) methods, allowing the detection of single copies of HPV, complicates the distinction between integrated and episomal HPV. Recently it has been suggested that, in such assays, the signals originating from integrated virus can be hidden in a background of episomal HPV. We therefore compared 2 different FISH protocols for the detection of integrated HPV in a series of CIN II/III lesions: 1) a mild protocol in which episomal HPV and RNA is retained and 2) a harsh protocol that extensively extracts proteins and RNA, and which promotes the partial loss of episomal HPV but not integrated HPV. A series of 28 HPV 16/18 positive CIN II/III lesions (17 solitary lesions and 11 lesions adjacent to microinvasive carcinoma) were studied. A punctate signal pattern was identified in 7 of these lesions with both protocols. Punctate signal was also present in control samples from lesions that are known to be associated with HPV integration (invasive squamous cell carcinoma (n = 3), adenocarcinoma in situ (n = 3), and invasive adenocarcinoma (n = 1). HPV RNA contributed significantly to the intensity of punctate FISH signal, especially when applying the mild protocol, as shown by omitting DNA denaturation, including RNase pretreatment steps and measuring the fluorescence signal intensity. Also, HPV RNA was frequently detected in addition to episomal/integrated HPV DNA in the majority of the other 21 CIN II/III lesions; this resulted in intense granular/diffuse FISH signals throughout the epithelium. However, in 7 of these lesions, the harsh protocol gave a more consistent punctate pattern in cells throughout the full thickness of the epithelium. This supports the hypothesis that the harsh protocol unmasks integrated HPV more efficiently by extracting RNA and episomal HPV. Overall, with this harsh protocol, a clonally expanded population of cells containing punctate HPV signals was found in 5 of 17 (29%) solitary CIN II/III lesions and in 9 of 11 (88%) CIN II/III lesions associated with microinvasive carcinoma. Combining these data with the results from our previous study, with the harsh protocol in 7 of 40 (18%) solitary CIN II/III lesions and 19/21 (90%) CIN II/III lesions associated with microinvasive carcinoma (p < 0.001), this pattern was found. This indicates that, when robustly defined, a punctate HPV pattern in CIN II/III lesions is associated with the presence of an invasive carcinoma. © 2005 Wiley‐Liss, Inc.